We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Diatron MI Plc

Develops, manufactures and markets hematology analyzers, clinical chemistry analyzers, and associated reagents for hu... read more Featured Products: More products

Download Mobile App

Diatron Exhibits Abacus 5 and Aquila Hematology Analyzers

By LabMedica International staff writers
Posted on 08 Feb 2017
Print article
Image: The Aquila hematology analyzer (Photo courtesy of Diatron).
Image: The Aquila hematology analyzer (Photo courtesy of Diatron).
Diatron, which develops, manufactures and markets hematology analyzers, and clinical chemistry analyzers, showcased its latest products, the Abacus 5 and Aquila hematology analyzers, at MEDLAB 2017, the world’s largest laboratory exhibition and congress in the Middle East.

One of the world’s top hematology analyzer manufacturers, the Hungarian company’s product range also includes hematology reagents, hematology control material, clinical chemistry analyzers, clinical chemistry reagents, and clinical chemistry controls.

At MEDLAB 2017, held at the Dubai International Convention & Exhibition Centre, UAE, from February 6-9, 2017, Diatron showcased the most advanced model in its range of hematology analyzers, the Abacus 5, which utilizes patented laser-based optical measurement technology developed by the company. The Abacus 5 provides a complete 26 parameter report, including optical determinations of the 5-part WBC differential count. It offers open and closed tube sampling options and has a throughput of 60 samples per hour in either stat or autoloader mode. The Abacus 5 hematology analyzer is one of the smallest 5-part differential analyzers available in the market and requires minimal bench space, thus making it ideal for use in space-restricted environments such as clinics and small to medium laboratories.

Diatron also exhibited Aquila, a 3-part differential hematology analyzer that can be used in any testing location and application where high quality CBC results are desired. The Diatron Aquila provides 3-part differential hematology results using less than 20 μl of whole blood and can operate in a closed or open tube mode. The system has a throughput of up to 60 tests per hour, and its compact size and unique on board reagent pack means that it requires little work and storage space. The Diatron Aquila can easily be moved from testing site to testing site and has an optional battery pack to support mobile testing needs and/or un-reliable main power supply locations.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Magnetic Bead Separation Modules

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more


view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.